ribosomal protein L23a pseudogene 88Genealiases: []
Q-omics provides the consensus-scored RPL23AP88 profile across patient tissues and cancer cell-line models. RPL23AP88 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, RPL23AP88 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, RPL23AP88 RNA expression shows 12,445 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight READ, LIHC, and UVM as cancer lineages where RPL23AP88 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23AP88 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23AP88 survival associations across molecular data types. RPL23AP88 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23AP88 RNA expression–survival associations across cancer types. High RPL23AP88 expression shows unfavorable associations in CESC, HNSC and LUSC, but favorable associations in READ, KIRC and CHOL. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for RPL23AP88 RNA expression.
This table summarizes RPL23AP88 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23AP88. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23AP88 shows lower tumor expression in LUAD and higher tumor expression in LIHC, KIRP, PRAD, BRCA and HNSC. The LIHC box plot shows higher RPL23AP88 RNA expression in tumor versus normal tissue (log2 FC = +0.108, t-test p < 0.001).
This table shows molecular features associated with RPL23AP88 in patient tissues and cancer cell lines. In patient samples, RPL23AP88 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
